Pfizer Inc.PFENYSE
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank23
Year-over-Year Change
Year-over-year research & development expense growth
Percentile
P23
Within normal range
vs 5Y Ago
-0.3x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -13.16% |
| Q3 2025 | 61.11% |
| Q2 2025 | 12.12% |
| Q1 2025 | -27.78% |
| Q4 2024 | 17.62% |
| Q3 2024 | -4.15% |
| Q2 2024 | 7.90% |
| Q1 2024 | -10.57% |
| Q4 2023 | 3.39% |
| Q4 2023 | 2.02% |
| Q3 2023 | 5.41% |
| Q2 2023 | -31.01% |
| Q4 2022 | 34.09% |
| Q4 2022 | -4.23% |
| Q3 2022 | 22.34% |
| Q2 2022 | -61.10% |
| Q4 2021 | 120.63% |
| Q4 2021 | 19.74% |
| Q3 2021 | 12.29% |
| Q2 2021 | -40.51% |
| Q4 2020 | 45.80% |
| Q3 2020 | 10.80% |
| Q2 2020 | 23.73% |
| Q1 2020 | -40.41% |
| Q4 2019 | 23.42% |
| Q3 2019 | 24.52% |
| Q2 2019 | 7.96% |
| Q1 2019 | -30.49% |
| Q4 2018 | 22.06% |
| Q3 2018 | 11.68% |
| Q3 2018 | 3.05% |
| Q2 2018 | -24.61% |
| Q4 2017 | 24.54% |
| Q4 2017 | 4.17% |
| Q3 2017 | 4.41% |
| Q2 2017 | -32.01% |
| Q4 2016 | 33.65% |
| Q4 2016 | 7.09% |
| Q3 2016 | 0.98% |
| Q2 2016 | -26.28% |